10 Takeover Targets to Watch This Fall
Does Pfizer’s Xeljanz share its CV safety questions with burgeoning JAK class?
Drugmakers vie to capture slice of rheumatoid arthritis market
2018 is already half over, but expect fireworks now that President Trump has turned his attention to seeking lower drug prices. The Tweeter-in-Chief publicly shamed companies that have tried to … Continue Reading 7 companies to watch during Q2 earnings